Very Early Relapse (< 1 year) in de novo Metastatic Seminoma is Associated With Reduced Overall Survival
Open Access
- 16 April 2025
- journal article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (4) , 102347
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines OfficeEuropean Urology Oncology, 2023
- Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS)European Urology Oncology, 2023
- European Association of Urology Guidelines on Testicular Cancer: 2023 UpdateEuropean Urology, 2023
- Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trialThe Lancet Oncology, 2022
- Human chorionic gonadotropin–positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3)European Journal of Cancer, 2020
- Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissectionEuropean Radiology, 2019
- ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-upAnnals of Oncology, 2018
- A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell TumorsClinical Genitourinary Cancer, 2017
- Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell TumoursEuropean Urology, 2017
- Late recurrence in 1263 men with testicular germ cell tumorsCancer, 2002